학술논문
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Document Type
article
Author
Kirsten E. Lyke; Robert L. Atmar; Clara Dominguez Islas; Christine M. Posavad; Meagan E. Deming; Angela R. Branche; Christine Johnston; Hana M. El Sahly; Srilatha Edupuganti; Mark J. Mulligan; Lisa A. Jackson; Richard E. Rupp; Christina A. Rostad; Rhea N. Coler; Martín Bäcker; Angelica C. Kottkamp; Tara M. Babu; David Dobrzynski; Judith M. Martin; Rebecca C. Brady; Robert W. Frenck; Kumaravel Rajakumar; Karen Kotloff; Nadine Rouphael; Daniel Szydlo; Rahul PaulChoudhury; Janet I. Archer; Sonja Crandon; Brian Ingersoll; Amanda Eaton; Elizabeth R. Brown; M. Juliana McElrath; Kathleen M. Neuzil; David S. Stephens; Diane J. Post; Bob C. Lin; Leonid Serebryannyy; John H. Beigel; David C. Montefiori; Paul C. Roberts; the DMID 21-0012 Study Group
Source
npj Vaccines, Vol 8, Iss 1, Pp 1-10 (2023)
Subject
Language
English
ISSN
2059-0105
Abstract
Abstract As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.